On this page
Tirzepatide is a once-weekly injection that switches on two gut-hormone receptors at once, GIP and GLP-1. In the 72-week SURMOUNT-1 trial (NEJM, 2022), adults with obesity and no diabetes lost an average of 15% to 21% of their body weight, depending on dose, versus about 3% on placebo. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management.
Tirzepatide is the active ingredient behind two of the most talked-about injections in medicine right now. It is the newer of the two big GLP-1-class drugs, and in head-to-head terms it has produced the largest average weight loss any prescription medication has shown in a major trial.
What sets it apart is mechanical. Most of these drugs copy one gut hormone. Tirzepatide copies two. Here is what that means in practice, how the two brand names differ, and what the trial numbers actually say.
What tirzepatide is
Tirzepatide is a dual agonist. It activates the receptors for two hormones your gut releases after you eat: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Older drugs in this family, like semaglutide, act on the GLP-1 receptor alone. According to the tirzepatide review in StatPearls (NCBI, 2024), hitting both receptors improves blood-sugar control and appetite regulation through more than one pathway.
In day-to-day terms, that translates to a familiar set of effects:
- Slower stomach emptying, so a meal keeps you full longer.
- Quieter appetite signaling in the brain, which turns down hunger and the constant pull toward food.
- Steadier blood sugar after eating, the effect it was first approved to deliver in diabetes.
You take it as a small subcutaneous injection once a week. Treatment starts at a low dose and steps up over a couple of months, which gives your body time to adjust and keeps early nausea manageable. We cover that side of it in the guide to GLP-1 side effects.
Mounjaro vs. Zepbound
Same molecule, two names. The difference is the condition each brand is approved to treat, not the drug inside the pen.
- Mounjaro is tirzepatide approved for type 2 diabetes.
- Zepbound is the same tirzepatide approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition.
The FDA approved Zepbound for weight management in late 2023, then in December 2024 it cleared Zepbound as the first medication for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA, 2024). That second approval matters because sleep apnea and obesity travel together so often, and it is the first drug to treat the apnea itself rather than just the symptoms.
If you have heard people use "Mounjaro for weight loss," they are usually describing tirzepatide prescribed off-label. The weight-management approval lives under the Zepbound name.
How much weight people lose
The headline data comes from SURMOUNT-1, published in the New England Journal of Medicine by Jastreboff and colleagues (2022). It enrolled 2,539 adults with obesity and no diabetes and ran for 72 weeks. Average weight loss tracked closely with dose:
- 5 mg weekly: about 15.0% of body weight.
- 10 mg weekly: about 19.5%.
- 15 mg weekly: about 20.9%, versus roughly 3.1% on placebo.
The distribution is as striking as the averages. At the top dose, 57% of participants lost at least 20% of their starting weight, compared with 3% of the placebo group. For a non-surgical treatment, that is territory earlier weight-loss drugs never reached. One honest caveat: these are averages from a controlled trial, and individual results vary widely. A real number for you depends on the dose you reach, how your body responds, and what you pair it with.
Why the dual action matters
The case for the GIP-plus-GLP-1 design is that two complementary signals may do more together than GLP-1 alone, and the trial weight-loss numbers are consistent with that idea. It is worth staying grounded here. The dual mechanism is a plausible reason tirzepatide tends to edge ahead, but trial design and dose differ between drugs, so the cleaner comparison is the data, not the biology.
A second receptor isn't magic. It gives the drug another lever on appetite and metabolism, and in the trials that shows up as a few more points of weight loss on average.
— John Venzor, DO
If you want that comparison spelled out against the other major option, our semaglutide vs. tirzepatide guide puts the results, dosing, and side effects side by side, and the semaglutide overview covers the GLP-1-only drug on its own.
One thing the mechanism doesn't change: tirzepatide is a treatment you stay on, not a course you finish. Weight tends to return after people stop, which is why it works best alongside steady changes to eating and activity rather than in place of them.
Tirzepatide is not for everyone. Do not use it if you or a close family member has had medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), or if you have a history of pancreatitis. It is not recommended during pregnancy or breastfeeding.
Get medical care promptly for severe or persistent abdominal pain (which can signal pancreatitis), a lump or swelling in the neck, or signs of a serious allergic reaction. A clinician reviews your full history before prescribing.